Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.
Mark Grayson

Mark Grayson Mark Grayson is deputy vice president of public affairs at PhRMA focusing on intellectual property, trade and international issues. Mark has been at PhRMA for more than 30 years joining PhRMA after a career with large public affairs firms focusing on FDA and financial issues. In his spare time Mark plays squash, bridge and takes long walks with his squirrel-chasing dog Teddy.

Recent Posts

How innovative medicines are benefiting countries across the globe

By Mark Grayson  |    March 1, 2017
It is important to look at costs across health care systems to fully understand how life-changing medicines are providing a more sustainable path forward. Across the globe, medicines are allowing...   Read More

PhRMA urges USTR to protect American innovators abroad

By Mark Grayson  |    February 10, 2017
Yesterday, PhRMA submitted comments for the 2017 Special 301 Report the Office of the U.S. Trade Representative (USTR) will publish in April. The comments highlight serious intellectual property...   Read More

New report provides recommendations for securing and protecting IP

By Mark Grayson  |    December 13, 2016
This week, the White House Office of the U.S. Intellectual Property Enforcement Coordinator (IPEC) issued a Joint Strategic Plan outlining actions government, industry, educational institutions...   Read More

New report highlights need to speed patent examination

By Mark Grayson  |    November 2, 2016
The Center for the Protection of Intellectual Property released a new report, “The Long Wait for Innovation: The Global Patent Pendency Problem,” documenting the growing global challenge of patent...   Read More

Study highlights negative impact of Canada's promise doctrine on R and D investment

By Mark Grayson  |    October 21, 2016
A newly published study from Charles River Associates (CRA) has found that Canada’s approach to intellectual property (IP), innovation and patient care is being jeopardized because of its adoption...   Read More

New report highlights impact of intellectual property on U.S. economy

By Mark Grayson  |    October 13, 2016
In late September, the U.S. Department of Commerce released a comprehensive report that found intellectual property (IP) intensive industries contribute more than $6 trillion (38.2 percent) to...   Read More

Fact Check Friday: The truth about biopharmaceutical patents

By Mark Grayson  |    August 26, 2016
MYTH: Biopharmaceutical companies use government-protected monopolies to raise costs on medicines. FACT: Patent-protected medicines routinely face competition from other brand name medicines,...   Read More

The next step towards Colombia’s future

By Mark Grayson  |    July 6, 2016
Just a few weeks ago in Havana, Colombia’s President Juan Manuel Santos and Commander of the Revolutionary Armed Forces of Colombia or FARC, Timoleon Jimenez, made history when they signed a peace...   Read More

Canada’s innovation challenge

By Mark Grayson  |    June 9, 2016
Canada is well-respected as a global leader. While no country is free of problems, Canada enjoys a strong economy, largely happy and healthy citizens and strong alliances with nations throughout...   Read More

Canada’s promise doctrine strikes again

By Mark Grayson  |    May 26, 2016
In just the last few weeks Canada has once again taken steps to invalidate yet another medicine (Zymar®) by applying the “promise doctrine.” See Allergan Inc. v. Apotex Inc., 2016 FC 344 (April 1,...   Read More

Search the Catalyst

View Posts by Topic

see all

Subscribe to Email Updates